Latest Articles
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
Published: April 13, 2026, midnight
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM
GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO
GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WKZO
GSK sees blockbuster potential in targeted cancer therapy after promising early data WKZO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WSAU
GSK sees blockbuster potential in targeted cancer therapy after promising early data WSAU
Published: April 12, 2026, 8:44 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
Published: April 12, 2026, 2:25 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK
Published: April 12, 2026, 2:25 p.m.
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today
Published: April 10, 2026, 4:35 p.m.
In ovarian cancer, one drug target towers up to 100-fold above rivals - Stock Titan
In ovarian cancer, one drug target towers up to 100-fold above rivals Stock Titan
Published: April 10, 2026, 11 a.m.
Link copied to clipboard!